Beth Chasen

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +17

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Simron Singh, Daniel Halperin, Sten Myrehaug et al. · The Lancet · 2024 · 324 citations · Full text

Medicine, Oncology, Pharmacology +17

Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients

Michael T. Tetzlaff, Kelly C. Nelson, Adi Diab et al. · Journal for ImmunoTherapy of Cancer · 2018 · 157 citations · Full text

Medicine, Dermatology, Oncology +17

Epidemiology of Neuroendocrine Neoplasms in the US

Arvind Dasari, Katrine L. Wallace, Daniel M. Halperin et al. · JAMA Network Open · 2025 · 63 citations · Full text

Medicine, Oncology, Pathology +17

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

Yasuhiro Oki, Hubert H. Chuang, Beth Chasen et al. · British Journal of Haematology · 2014 · 52 citations · Full text

Medicine, Oncology, Radiology +17